Evaluation of a Scaling Approach for the Bioequivalence of Highly Variable Drugs
Journal Title: The AAPS Journal - Year 2008, Vol 10, Issue 3
Abstract
Various approaches for evaluating the bioequivalence (BE) of highly variable drugs (CV ≥ 30%) have been debated for many years. More recently, the FDA conducted research to evaluate one such approach: scaled average BE. A main objective of this study was to determine the impact of scaled average BE on study power, and compare it to the method commonly applied currently (average BE). Three-sequence, three period, two treatment partially replicated cross-over BE studies were simulated in S-Plus. Average BE criteria, using 80–125% limits on the 90% confidence intervals for Cmax and AUC geometric mean ratios, as well as scaled average BE were applied to the results. The percent of studies passing BE was determined under different conditions. Variables tested included within subject variability, point estimate constraint, and different values for σw0, which is a constant set by the regulatory agency. The simulation results demonstrated higher study power with scaled average BE, compared to average BE, as within subject variability increased. At 60% CV, study power was more than 90% for scaled average BE, compared with about 22% for average BE. A σw0 value of 0.25 appears to work best. The results of this research project suggest that scaled average BE, using a partial replicate design, is a good approach for the evaluation of BE of highly variable drugs.
Authors and Affiliations
Sam H. Haidar, Fairouz Makhlouf, Donald J. Schuirmann, Terry Hyslop, Barbara Davit, Dale Conner, Lawrence X. Yu
Keywords
Related Articles
- EP ID EP681630
- DOI 10.1208/s12248-008-9053-4
- Views 93
- Downloads 0
Effect of nonionic surfactant on transport of surface-active and non-surface-active model drugs and emulsion stability in triphasic systems
Pharmacodynamic Studies to Demonstrate Bioequivalence of Oral Inhalation Products
In the session on “Pharmacodynamic studies to demonstrate efficacy and safety”, presentations were made on methods of evaluating airway deposition of inhaled corticosteroids and bronchodilators, and syste...
Pharmacogenomics: The promise of personalized medicine
Recommendations for Validation of LC-MS/MS Bioanalytical Methods for Protein Biotherapeutics
This paper represents the consensus views of a cross-section of companies and organizations from the USA and Canada regarding the validation and application of liquid chromatography tandem mass spectrometry (LC-MS/MS) me...
Effective Absorption Modeling in Relative Bioavailability Study Risk Assessment
Absorption modeling is an excellent strategic fit to perform a risk assessment for relative bioavailability (RBA) studies as it provides direct input into the question that is at the core of the RBA decision, namely, how...